JMP Securities Analysts Give Blueprint Medicines (BPMC) a $109.00 Price Target

JMP Securities set a $109.00 price objective on Blueprint Medicines (NASDAQ:BPMC) in a research report released on Monday morning. The brokerage currently has a buy rating on the biotechnology company’s stock.

Several other equities analysts also recently issued reports on the stock. Zacks Investment Research raised shares of Blueprint Medicines from a hold rating to a buy rating and set a $87.00 price objective on the stock in a research note on Monday, January 8th. Cowen reissued a buy rating on shares of Blueprint Medicines in a research note on Wednesday, February 21st. ValuEngine raised shares of Blueprint Medicines from a hold rating to a buy rating in a research note on Monday, April 2nd. Finally, BidaskClub raised shares of Blueprint Medicines from a hold rating to a buy rating in a research report on Friday, February 23rd. One investment analyst has rated the stock with a sell rating and twelve have issued a buy rating to the company’s stock. Blueprint Medicines presently has an average rating of Buy and a consensus target price of $87.80.

How to Become a New Pot Stock Millionaire

Shares of BPMC opened at $83.25 on Monday. The company has a current ratio of 15.98, a quick ratio of 15.98 and a debt-to-equity ratio of 0.02. The company has a market cap of $3,854.26, a P/E ratio of -21.24 and a beta of 0.97. Blueprint Medicines has a 1 year low of $34.38 and a 1 year high of $109.00.



Blueprint Medicines (NASDAQ:BPMC) last announced its quarterly earnings data on Wednesday, February 21st. The biotechnology company reported ($1.23) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.07) by ($0.16). The firm had revenue of $1.63 million for the quarter, compared to analysts’ expectations of $5.28 million. Blueprint Medicines had a negative net margin of 691.30% and a negative return on equity of 38.79%. The business’s quarterly revenue was down 78.8% on a year-over-year basis. During the same period in the previous year, the company posted ($0.75) EPS. equities analysts predict that Blueprint Medicines will post -4.85 EPS for the current year.

In other news, insider Kate Haviland sold 6,775 shares of the stock in a transaction on Monday, February 12th. The shares were sold at an average price of $74.93, for a total value of $507,650.75. Following the completion of the sale, the insider now owns 12,649 shares of the company’s stock, valued at $947,789.57. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Daniel Lynch sold 17,500 shares of the stock in a transaction on Monday, February 12th. The stock was sold at an average price of $74.84, for a total transaction of $1,309,700.00. Following the completion of the sale, the director now directly owns 202,812 shares of the company’s stock, valued at approximately $15,178,450.08. The disclosure for this sale can be found here. Insiders have sold 89,567 shares of company stock valued at $7,651,106 in the last ninety days. 3.40% of the stock is currently owned by company insiders.

Several institutional investors have recently added to or reduced their stakes in BPMC. Zurcher Kantonalbank Zurich Cantonalbank increased its position in shares of Blueprint Medicines by 57.3% in the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,866 shares of the biotechnology company’s stock worth $141,000 after acquiring an additional 680 shares in the last quarter. QS Investors LLC acquired a new stake in shares of Blueprint Medicines in the fourth quarter worth $173,000. First Mercantile Trust Co. acquired a new stake in shares of Blueprint Medicines in the fourth quarter worth $183,000. Tower Research Capital LLC TRC increased its position in shares of Blueprint Medicines by 942.7% in the fourth quarter. Tower Research Capital LLC TRC now owns 2,513 shares of the biotechnology company’s stock worth $190,000 after acquiring an additional 2,272 shares in the last quarter. Finally, Public Employees Retirement Association of Colorado acquired a new stake in shares of Blueprint Medicines in the fourth quarter worth $227,000. 97.75% of the stock is owned by institutional investors.

ILLEGAL ACTIVITY WARNING: “JMP Securities Analysts Give Blueprint Medicines (BPMC) a $109.00 Price Target” was originally reported by StockNewsTimes and is the sole property of of StockNewsTimes. If you are accessing this story on another publication, it was copied illegally and republished in violation of United States and international copyright & trademark laws. The original version of this story can be accessed at https://stocknewstimes.com/2018/04/20/jmp-securities-analysts-give-blueprint-medicines-bpmc-a-109-00-price-target.html.

Blueprint Medicines Company Profile

Blueprint Medicines Corporation, a biopharmaceutical company, develops drugs of small molecule kinase inhibitors that target genomic drivers in various cancers and a rare genetic disease. Its lead drug candidates include avapritinib, which is in Phase I clinical trials that targets KIT Exon 17 mutant proteins and PDGFRa D842V mutations, that are drivers of cancer and proliferative disorders, including gastrointestinal stromal tumors and systemic mastocytosis; and BLU-554, which is in Phase I clinical trials an orally available, potent, and irreversible inhibitor of the kinase FGFR4 that is activated in a defined subset of patients with hepatocellular carcinoma.

Analyst Recommendations for Blueprint Medicines (NASDAQ:BPMC)

Receive News & Ratings for Blueprint Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Blueprint Medicines and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply